Can a smart drug cross the Blood-Brain barrier to attack breast cancer metastases?

NCT ID NCT06176261

Recruiting now Disease control Sponsor: Nancy Lin, MD Source: ClinicalTrials.gov ↗

First seen Aug 06, 2026 · Last updated Aug 07, 2026 · Updated 1 time

Summary

This phase 2 trial is testing whether the investigational drug datopotamab deruxtecan (Dato-DXd) can safely and effectively treat HER2-negative breast cancer that has spread to the brain. The study enrolls adults with metastatic breast cancer who have brain metastases that are either newly diagnosed or progressing after prior treatment. Participants receive the drug by intravenous infusion, and researchers will measure how many people experience tumor shrinkage in the brain and body.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Datopotamab deruxtecan (Dato-DXd), an antibody-drug conjugate given by intravenous infusion
What this could lead to: If effective, this treatment could offer a new option for people with breast cancer that has spread to the brain, potentially shrinking tumors and improving outcomes.
What could go wrong: This is a phase 2 trial with a modest number of participants, so results may not be conclusive. The drug may cause side effects, and its effectiveness in brain metastases is not yet established.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm estrogen-receptor negative breast cancer estrogen-receptor positive breast cancer female breast carcinoma Her2-receptor negative breast cancer hormone receptor-positive breast cancer triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER BREAST CANCER FEMALE ER POSITIVE BREAST CANCER ER-NEGATIVE BREAST CANCER HER2-NEGATIVE BREAST CANCER HER2-NEGATIVE BREAST CARCINOMA METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA

Contacts and locations

Locations

Dana-Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States
Duke University Medical Center
RECRUITING

Durham, North Carolina, 27710, United States
Miami Baptist Cancer Institute/
RECRUITING

Miami, Florida, 33176, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.